Thoracic SMARCA4-deficient undifferentiated tumor-a case of an aggressive neoplasm-case report

Anja C Roden1

  • 1Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN, USA.

Insights

Aggressive thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) are linked to SMARCA4 gene mutations and poor prognosis. This case highlights diagnostic challenges and potential therapeutic avenues like EZH2 and anti-PD-1 inhibitors.

Area of Science:

  • Oncology
  • Genetics
  • Pathology

Background:

  • Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) are aggressive neoplasms.
  • They are characterized by inactivating mutations in the SMARCA4 gene, leading to loss of brahma-related gene 1 (BRG1) expression.

Observation:

  • The case involves a 66-year-old male smoker presenting with mediastinal and suprahilar masses and widespread metastatic disease.
  • Biopsy revealed extensive necrosis and neoplastic epithelioid cells with rhabdoid cytology, lacking keratin and other differentiation markers, but with focal CD30 expression.

Findings:

  • Tumor cells demonstrated loss of BRG1 expression while preserving INI-1 expression.
  • This immunophenotype, combined with clinical presentation, led to the diagnosis of SMARCA4-UT.

Implications:

  • SMARCA4-UT typically presents with metastatic disease and has a poor median survival of approximately six months.
  • Ongoing clinical trials are investigating EZH2 inhibitors, and rare successful treatments with anti-PD-1 inhibitors offer potential therapeutic strategies.

Related Concept Videos